AAAAAA

   
Results: 1-2 |
Results: 2
Phase I trial of 6-hour infusion of glufosfamide, a new alkylating agent with potentially enhanced selectivity for tumors that overexpress transmembrane glucose transporters: A study of the European Organization for Researchand Treatment of Cancer Early Clinical Studies Group
Authors: Briasoulis, E Judson, I Pavlidis, N Beale, P Wanders, J Groot, Y Veerman, G Schuessler, M Niebch, G Siamopoulos, K Tzamakou, E Rammou, D Wolf, L Walker, R Hanauske, A
Citation: E. Briasoulis et al., Phase I trial of 6-hour infusion of glufosfamide, a new alkylating agent with potentially enhanced selectivity for tumors that overexpress transmembrane glucose transporters: A study of the European Organization for Researchand Treatment of Cancer Early Clinical Studies Group, J CL ONCOL, 18(20), 2000, pp. 3535-3544
Phase I study of Carzelesin (U-80,244) given (4-weekly) by intravenous bolus schedule
Authors: Awada, A Punt, CJA Piccart, MJ Van Tellingen, O Van Manen, L Kerger, J Groot, Y Wanders, J Verweij, J Wagener, DJT
Citation: A. Awada et al., Phase I study of Carzelesin (U-80,244) given (4-weekly) by intravenous bolus schedule, BR J CANC, 79(9-10), 1999, pp. 1454-1461
Risultati: 1-2 |